Related references
Note: Only part of the references are listed.Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF)
Hartmut Link
SUPPORTIVE CARE IN CANCER (2022)
Invasive fungal disease and the immunocompromised host including allogeneic hematopoietic cell transplant recipients: Improved understanding and new strategic approach with sargramostim
Sherman Chu et al.
CLINICAL IMMUNOLOGY (2021)
Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: A systematic review and Bayesian network meta-analysis
Yong Wang et al.
SCIENTIFIC REPORTS (2019)
Effectiveness of Filgrastim and Polyethylene Glycol-Filgrastim in the Treatment of Postchemotherapy Neutropenia in Children: Phase I Clinical Trial
Saeed Yousofian et al.
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY (2019)
A Guide for Systematic Reviews: PRISMA
Ayse Adin Selcuk
TURKISH ARCHIVES OF OTORHINOLARYNGOLOGY (2019)
Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events
T. Christopher Bond et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2018)
Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update
Randy A. Taplitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia
Paul Cornes et al.
ADVANCES IN THERAPY (2018)
Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update
Thomas Lehrnbecher et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions
Xiao Jun Wang et al.
CURRENT ONCOLOGY REPORTS (2017)
Modulating host immune responses to fight invasive fungal infections
James E. Scriven et al.
CURRENT OPINION IN MICROBIOLOGY (2017)
Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy-a representative sample survey in Germany
Hartmut Link et al.
SUPPORTIVE CARE IN CANCER (2016)
A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('SPROG' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN
R. C. F. Leonard et al.
ANNALS OF ONCOLOGY (2015)
The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy
G. H. Lyman et al.
ANNALS OF ONCOLOGY (2015)
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
Thomas J. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The Method Quality of Cross-Over Studies Involved in Cochrane Systematic Reviews
Hong Ding et al.
PLOS ONE (2015)
Towards a less invasive approach to the early goal-directed treatment of septic shock in the ED
Daniele Coen et al.
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2014)
G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use
Gisoo Barnes et al.
CANCER MEDICINE (2014)
Development of the Hematopoietic System and Disorders of Hematopoiesis that Present During Infancy and Early Childhood
Karen S. Fernandez et al.
PEDIATRIC CLINICS OF NORTH AMERICA (2013)
Myelosuppression grading of chemotherapies for hematologic malignancies to facilitate communication between medical and dental staff: lessons from two cases experienced odontogenic septicemia
Masaya Akashi et al.
BMC ORAL HEALTH (2013)
Developmental changes in hematopoietic stem cell properties
Michael R. Copley et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2013)
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)
A. J. Ullmann et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia
Pierre Rofail et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2012)
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
Alison G. Freifeld et al.
CLINICAL INFECTIOUS DISEASES (2011)
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
M. S. Aapro et al.
EUROPEAN JOURNAL OF CANCER (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Phase II, Randomized, Open- Label Study of Pegfilgrastim-Supported VDC/IE Chemotherapy in Pediatric Sarcoma Patients
Sheri L. Spunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors
S. Kelly et al.
BRITISH JOURNAL OF CANCER (2009)
Retrospective Comparison of Neutropenia in Children With Ewing Sarcoma Treated With Chemotherapy and Granulocyte Colony-Stimulating Factor (G-CSF) or Pegylated G-CSF
Emilie Milano-Bausset et al.
CLINICAL THERAPEUTICS (2009)
Pegfilgrastim for Prevention of Chemotherapy-Associated Neutropenia in Pediatric Patients With Solid Tumors
Scott C. Borinstein et al.
PEDIATRIC BLOOD & CANCER (2009)
Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma
Ulrich J. M. Mey et al.
SUPPORTIVE CARE IN CANCER (2007)
Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy
Nicolas Andre et al.
ANTI-CANCER DRUGS (2007)
Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use
Howard Ozer et al.
ONCOLOGIST (2007)
Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
D Weycker et al.
ANNALS OF PHARMACOTHERAPY (2006)
Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma
B Pro et al.
LEUKEMIA & LYMPHOMA (2006)
Pegfilgrastim in pediatric cancer patients
EM te Poele et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2005)
Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma
G Wendelin et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2005)
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: A meta-analysis of randomized controlled trials
L Sung et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Methodological index for non-randomized studies (MINORS):: Development and validation of a new instrument
K Slim et al.
ANZ JOURNAL OF SURGERY (2003)
Share Paper
